The fact that incubation with an GAPDH inhibitor led to a stronger decrease in viability of tumor cells than of normal (healthy) cells supports the hypothesis that melanoma cells are more prone to glycolysis than normal cells. The gene discussed is GAPDH; the disease is melanoma.